Isoniazid-rifampin-induced hepatitis in hepatitis B carriers.
From January 1984-December 1987, 1783 patients received combination therapy of isoniazid, rifampin, and ethambutol for the control of tuberculosis. Forty-two developed symptomatic hepatitis during the period of treatment. Fifteen were hepatitis B virus carriers, and the remaining 27 were noncarriers. The peak serum transaminase and bilirubin levels were higher in carriers. Seven carriers died of fulminant or subacute hepatic failure, and only 1 noncarrier died. Eleven carriers had detectable serum hepatitis B virus deoxyribonucleic acid during the acute stage of hepatitis. The roles of isoniazid-rifampin combination therapy and hepatitis B virus in the adverse outcomes of carriers were discussed.
Wu
J C
JC
Department of Medicine, Veterans General Hospital, Taipei, Taiwan, Republic of China.
Lee
S D
SD
Yeh
P F
PF
Chan
C Y
CY
Wang
Y J
YJ
Huang
Y S
YS
Tsai
Y T
YT
Lee
P Y
PY
Ting
L P
LP
Lo
K J
KJ
D002353:Carrier State; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D006509:Hepatitis B / Q000150:complications*; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012293:Rifampin / Q000009:adverse effects* / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin